OUP has injected follow-on funding into Palladio, creators of a drug for autosomal dominant polycystic kidney disease.

SoftBank Vision Fund 2, PICC Group and Morningside Venture Capital co-led the round, which also attracted Tencent, China Life Insurance, SIG China and others.

Tencent joined GL Ventures and YF Capital to co-lead a $176m funding round for Taimei Technology, while SoftBank China Venture Capital also invested.

Lilly Asia Ventures has returned for a $147m series D round that will allow InventisBio to advance its treatments for breast cancer and gout into phase 2 clinical trials.

GV has thrown its weight behind Monte Rosa Therapeutics, which is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

Creative Biosciences has collected $88m in fresh funding from a consortium of new and existing shareholders, though Kingmed Diagnostics and Tasly did not return.

Creative Biosciences has collected $88m in fresh funding, five years after being founded by a Sun Yat-Sen University professor.

Novo and Bristol Myers-Squibb formed part of a group of new and existing backers that provided cash to Galecto, based on research from the universities of Lund and Edinburgh.

A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.